The 15% Cap That Almost Broke University Research: Inside the $5.24 Billion NIH Indirect Cost Battle

On February 7, 2025, the National Institutes of Health posted Notice NOT-OD-25-068 — a three-page policy document that, had it survived, would have redirected more money away from American research universities than any single federal action in the history of academic science. The notice imposed a 15% cap on indirect cost recovery for all new NIH grants and, controversially, for existing awards to institutions of higher education, effective February 10.

Three days. That was the notice period the agency gave universities to absorb a policy change that independent analysis projected would strip $5.24 billion annually from higher education research infrastructure.

Fourteen days after the notice was posted, a federal judge in Massachusetts issued a temporary restraining order. Two months later, the same judge issued a permanent injunction. Nine months after that, the First Circuit Court of Appeals upheld the injunction in a ruling that effectively killed the policy — for now. Congress then reinforced the judicial outcome by including language in the FY2026 appropriations bill preventing HHS from implementing any modified indirect cost rate approach.

The cap is dead. The fight over what replaces it is very much alive.

What Indirect Costs Actually Pay For

The term "indirect costs" — formally called Facilities and Administrative (F&A) costs — is among the most misunderstood concepts in research funding. Critics describe them as overhead, administrative bloat, or a tax on taxpayers. The reality is more mechanical and less scandalous.

When a university receives a $1 million NIH grant to study, say, the molecular mechanisms of Alzheimer's disease, the direct costs fund the research itself: salaries for the principal investigator and postdocs, reagents, equipment, animal care, travel to conferences. The indirect costs fund everything the university provides to make that research possible: the building the lab occupies (depreciation, utilities, maintenance), the institutional review board that ensures human subjects protections, the biosafety committee that monitors pathogen handling, the grants management office that tracks federal compliance, the library that provides journal access, the IT infrastructure that stores and secures research data.

These are not luxuries. They are federally mandated requirements. The NIH requires biosafety committees. It requires IRB review. It requires data management plans and research security training. Every one of these requirements costs money to implement, and that money comes from indirect cost recovery.

Negotiated F&A rates vary by institution but typically range from 50% to 60% of modified total direct costs at major research universities. The national average across all institutions is approximately 37.2%. These rates are not self-reported — they are negotiated with the federal government through a detailed audit process managed by the Office of Naval Research or the Department of Health and Human Services, depending on the institution. The negotiation occurs every three to four years and involves documentation of actual costs.

A 15% cap would have cut the average university's indirect cost recovery by more than half. For institutions with negotiated rates above 50%, the cut would have exceeded 70%.

The Dollar-by-Dollar Impact

Researchers at several institutions modeled the financial impact using FY2024 data from the NIH RePORTER database. The results were staggering.

Under the proposed cap, institutions of higher education would have lost $5.24 billion annually — $2.99 billion from public universities and $2.25 billion from private institutions. The three hardest-hit states by absolute dollar loss: California ($804 million), New York ($632 million), and Texas ($310 million). On a per-capita basis, Connecticut ($48.03 per person), Maryland ($35.03), the District of Columbia ($32.58), and Massachusetts ($31.69) would have suffered the deepest relative losses.

To understand what $5.24 billion means in practical terms, consider a single institution. A research university receiving $100 million in annual NIH funding with a negotiated F&A rate of 55% currently recovers $55 million in indirect costs. Under the 15% cap, that recovery drops to $15 million — a $40 million annual gap. That gap does not come out of the research budget. It comes out of the institutional budget: fewer compliance staff, deferred building maintenance, reduced IT security, smaller grants management offices.

The downstream effects would have been severe. IRB and regulatory compliance functions, secure data warehousing, hazardous waste disposal, and other critical research safety services would have contracted. Small and emerging research universities — institutions working to build their research capacity — would have been hit hardest proportionally, as they lack the endowment cushions and alternative revenue streams that buffer Harvard and Stanford.

The Legal Battle: From TRO to Permanent Injunction

The legal response was swift and overwhelming. On February 21, 2025, U.S. District Judge Angel Kelley in Boston extended a temporary restraining order blocking implementation. The case was brought by a coalition of major research universities and higher education associations arguing that the policy was arbitrary, failed to follow required notice-and-comment procedures, and exceeded the agency's statutory authority.

On April 4, 2025, Judge Kelley issued a permanent injunction. The ruling found that the NIH had failed to provide adequate justification for the 15% rate, had not followed the Administrative Procedure Act's requirements for notice-and-comment rulemaking, and had not accounted for the policy's impact on research safety and compliance infrastructure.

The Trump administration appealed on April 8, 2025. The case moved to the First Circuit Court of Appeals, which upheld the permanent injunction on January 5, 2026. The appellate ruling was decisive: the court found that the policy change was substantive enough to require formal rulemaking, not a unilateral agency notice. The three-day implementation timeline — from announcement to enforcement — was cited as evidence of procedural inadequacy.

Congress Reinforces the Courts

Congress did not wait to see whether the administration would seek Supreme Court review. The Consolidated Appropriations Act for FY2026, signed January 23, 2026, included a provision that explicitly limits HHS from "developing or implementing a modified approach to determining indirect cost rates." The explanatory statement accompanying the appropriations directed HHS and other departments to engage in discussions with Congress on how to improve indirect cost rate policy — a signal that Congress wants a seat at the table for any future changes.

This legislative action converts what had been a judicial outcome — potentially reversible on appeal — into a statutory constraint. For the duration of FY2026, the administration cannot implement any version of the indirect cost cap without Congressional authorization. Whether a similar provision appears in FY2027 appropriations will depend on the political dynamics of the next budget cycle.

The Argument That Will Not Die

The 15% cap is dead as policy, but the argument that produced it — that indirect costs are too high, that universities are profiting from overhead, that more grant money should go to "direct research" — remains politically potent. The White House's FY2027 budget proposals are expected to revisit indirect cost reform in some form, potentially through a phased reduction rather than an abrupt cap.

The counterargument from the research community has been consistent: indirect costs fund federally mandated compliance requirements. You cannot require IRB review, biosafety committees, data management, and research security training while simultaneously refusing to pay for them. Cutting indirect cost recovery does not eliminate these costs — it shifts them to institutional budgets, which means tuition increases, deferred maintenance, and reduced hiring.

There is a legitimate policy conversation to be had about whether the current F&A rate negotiation process is optimally efficient, whether certain cost categories should be weighted differently, or whether emerging research institutions should receive rate-setting assistance. But that conversation requires the kind of deliberate, data-driven, stakeholder-inclusive process that the February 2025 notice conspicuously avoided.

What This Means for NIH Grant Seekers

The immediate threat has passed. Negotiated F&A rates remain in effect for all NIH awards in FY2026. Institutions should continue budgeting at their full negotiated rates, and reviewers should not penalize proposals for including standard indirect cost calculations.

Watch the FY2027 budget closely. The statutory protection in the FY2026 appropriations is a one-year provision. If the administration proposes a modified indirect cost approach in the FY2027 budget — even a phased one — the political battle will reignite. Organizations that depend on NIH funding should engage their Congressional representatives now, before the appropriations process reaches its decisive phase.

Understand fringe benefit implications. Many institutions bundle employee benefits — health insurance, retirement contributions — into their F&A cost pools. Had the 15% cap been implemented, institutions would have been forced to either increase fringe benefit rates charged to direct costs or absorb the gap institutionally. Either approach would have effectively increased the direct cost of research, reducing the amount of science each grant dollar buys. This dynamic is worth understanding even with the cap blocked, because any future reform that reduces F&A recovery will trigger the same cost-shifting.

Smaller institutions face disproportionate risk. If a future administration succeeds in implementing some form of indirect cost reduction, major research universities with diversified revenue — endowment income, clinical operations, technology licensing — will absorb the impact. Emerging research institutions, Historically Black Colleges and Universities, Tribal colleges, and primarily undergraduate institutions that are building research programs will face existential pressure. These institutions typically have higher proportional dependence on federal research funding and thinner financial margins.

Advocacy matters. The 15% cap was blocked because the higher education community mobilized rapidly, filed litigation within days, and coordinated messaging to Congress. The Council on Governmental Relations (COGR), the Association of American Medical Colleges (AAMC), the American Association of Universities (AAU), and individual institutions all played roles. That infrastructure needs to remain active, not demobilized, because the next iteration of this fight is coming.

The $5.24 billion stayed in the research system because institutions fought for it — in court, in Congress, and in the public square. The legal and legislative victories are real. But they are also temporary. For researchers and research administrators navigating NIH funding in 2026, the practical advice is simple: budget at your full negotiated rate, build your proposals on scientific merit, and stay connected to the policy landscape through tools like Granted that track both funding opportunities and the regulatory shifts that shape them.